Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16635898 | 0.91 | KDM4E (0.32) | PKMCHUKJAK2JAK1TYK2 | |
| SCHEMBL28974832 | 0.77 | — | — | |
| SCHEMBL25293416 | 0.77 | PLK1 (0.31) | PKM | |
| SCHEMBL22246568 | 0.76 | RAPGEF4 (0.32) | RAPGEF4PTGDR2JAK2JAK1TYK2 | |
| SCHEMBL28427713 | 0.73 | TDO2 (0.36) | PTGDR2JAK2JAK1TYK2JAK3 | |
| SCHEMBL28763509 | 0.72 | CACNA1B (0.33) | POLB | |
| SCHEMBL29905626 | 0.72 | — | — | |
| SCHEMBL3683774 | 0.72 | PDE5A (0.36) | HTR2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL22234302 | 0.72 | TDO2 (0.35) | MAPTJAK2JAK1TYK2JAK3 | |
| SCHEMBL11839119 | 0.72 | ALDH1A1 (0.33) | JAK2JAK1TYK2JAK3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| US-9023882-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| CN-101679244-B | 5-membered heterocyclic derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL | 2014-01-01 | — | — | CN | disclosed |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8227500-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-8227500-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-8227500-B2 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-09 | — | — | US | disclosed |
| CN-101679244-A | 5-membered heterocyclic derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL | 2010-03-24 | — | — | CN | disclosed |
| EP-2133331-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227864-A1 | 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, CBR1 | PKM 3025/4885RAPGEF4 4880/4885CHUK 410/4885 |
| US-20120289506-A1 | 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | XDH, DAO, DDO | PKM 2567/4885RAPGEF4 4880/4885CHUK 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.